Search research articles
Contact Us
Filters
Showing results (181-190 of 186) with videos related to
Page
of 19
Sort By:
You have reached the last page of results.
This site can display upto 186 results.
Nature Cell Biology
|
January 24, 2018
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER<sup>+</sup> breast cancer
Sylwia Gawrzak, Lorenzo Rinaldi, Sara Gregorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2015
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
Miguel Martín, Amparo Ruiz Simón, Manuel Ruiz Borrego, et al.
Cancer Cell
|
July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer
Krishna M Vasudevan, David A Barbie, Michael A Davies, et al.
Journal of the National Cancer Institute
|
May 29, 2008
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer
Miguel Martín, Alvaro Rodríguez-Lescure, Amparo Ruiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2019
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch, Carlos H Barrios, Laura Torrecillas, et al.
Plos One
|
May 12, 2011
A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene
Maider Ibarrola-Villava, Lara P Fernandez, Santos Alonso, et al.
Page
of 19
Search research articles
Search
Showing results (181-190 of 186) with videos related to
Sort By:
Page
of 19
You have reached the last page of results.
This site can display upto 186 results.
Nature Cell Biology
|
January 24, 2018
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER<sup>+</sup> breast cancer
Sylwia Gawrzak, Lorenzo Rinaldi, Sara Gregorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2015
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
Miguel Martín, Amparo Ruiz Simón, Manuel Ruiz Borrego, et al.
Cancer Cell
|
July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer
Krishna M Vasudevan, David A Barbie, Michael A Davies, et al.
Journal of the National Cancer Institute
|
May 29, 2008
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer
Miguel Martín, Alvaro Rodríguez-Lescure, Amparo Ruiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2019
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch, Carlos H Barrios, Laura Torrecillas, et al.
Plos One
|
May 12, 2011
A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene
Maider Ibarrola-Villava, Lara P Fernandez, Santos Alonso, et al.
Page
of 19